CHIMERIC THERAPEUTICS

ASX:CHM
Extraordinary General Meeting
Corporate Overview
11 June 2024

DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.

CHIMERIC THERAPEUTICS

CORPORATE PROFILE

Exchange	ASX: CHM
Share Price (6 June 2024)	$0.018
52 Week Range	$0.018- 0.047
Market Cap (6 June 2024)	~$14.67M

INVESTOR HIGHLIGHTS

Innovative Pipeline

3 Novel Cell Therapy Technologies

Early Clinical Promise

4 Phase 1 clinical trials open and enrolling
30+ Patients treated

Near Term Clinical Catalysts

Multiple clinical milestones over the next 12 months

Proven Expertise

Experienced team with a track record of driving development through to registration & commercialization

CHIMERIC'S BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials

CHM CDH17
CAR-T

Technology from:

Penn
University of Pennsylvania

Phase 1/2 Trial Open

Sarah Cannon Cancer Centre

CHM CLTX
CAR-T

Technology from:

Phase 1a Completed
City of Hope

Phase 1b Trial Open

Sarah Cannon Cancer Centre

CHM CORE-NK
"Off the shelf" NK

Technology from:

CASE WESTERN RESERVE UNIVERSITY

Phase 1b Trial Open

MD Anderson

Phase 1b Trial Open

Case Western

CHIMERIC: CHM CDH17 CAR-T Trial Open

CHM CDH17
CAR-T

Technology from:

Phase 1/2 Trial Open

Sarah Cannon Cancer Centre

PERSONALISED CAR-T: *Autologous*

First in class CDH17 CAR T for gastrointestinal cancers

FDA IND clearance
Nov 23

Phase 1/2 Trial Open in Colorectal Cancer, Gastric Cancer and Neuroendocrine tumours

CHM CDH17

Pre-Clinical Efficacy



CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models

Neuroendocrine Tumours



Gastric Cancer



Pancreatic Cancer



Source: Feng et al., Nature Cancer, 2022

CHIMERIC THERAPEUTICS: CHM CLTX CAR-T

CHM CLTX
CAR-T

Technology from:

Phase 1a Completed
City of Hope

Phase 1b Trial Open

Sarah Cannon Cancer Centre

PERSONALISED CAR-T: *Autologous*

First in class CLTX CAR T for brain cancer and solid tumours

Preliminary Positive Phase 1A Clinical Trial in Relapse/ Recurrent Glioblastoma

Ongoing Phase 1B Clinical Trial in Recurrent Glioblastoma

CHIMERIC: CHM CORE-NK

CHM CORE-NK
"Off the shelf" NK

Technology from:

CASE WESTERN RESERVE UNIVERSITY

Phase 1b Trial Open	Phase 1b Trial Open
MD Anderson	Case Western

Off the shelf: *Allogeneic*

NK cell expansion platform
Universal Donor

Positive Phase 1A Clinical Trial in Colorectal Cancer and AML

Two ongoing Phase 1B Clinical Trials in AML and CRC

AML: Cohort 1 cleared, moved to dose expansion for Cohort 2

Foundation for next generation armored platform and CAR NK assets

KEY CLINICAL CATALYSTS

Delivering in 2023 and Advancing Key Clinical Milestones in 2024

	2023 Achievements	2024 Milestones
CHM CDH17 CHM 2101	✓ FDA IND Clearance for Ph. 1/2 Trial in Colorectal Cancer, Gastric Cancer and Neuroendocrine tumours	✓ Ph. 1/2 Site Initiation • Ph. 1/2 1st Patient Treated • Ph. 1/2 Preliminary Dose Escalation Data
CHM CLTX CHM 1101	✓ Ph. 1A Dose Escalation Complete in GBM ✓ Ph. 1A Positive Preliminary Data in GBM ✓ Ph. 1B 1st Patient Treated in GBM	• Ph. 1B Dose Expansion 1st Patient Treated • Ph. 1B Preliminary Data
CHM CORE-NK CHM 0201	✓ Ph. 1B ADVENT AML Site Initiation ✓ Ph. 1B CHM CORE-NK 0201 + Vactosertib 1st Patient Treated	✓ Ph. 1B ADVENT AML 1st Patient Treated • Ph. 1B ADVENT AML Dose Escalation Complete • Ph. 1B ADVENT AML Preliminary Data

FOR MORE INFORMATION

www.chimerictherapeutics.com

www.linkedin.com/company/chimeric-therapeutics/

@chimeric9352

Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics Ltd
Melbourne Australia
T: +61498966180
investor@chimerictherapeutics.com

CHIMERIC THERAPEUTICS

APPENDIX

CHIMERIC LEADERSHIP TEAM

EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION

EXPERIENCE

75+ Years of Cell Therapy Experience

JUNO THERAPEUTICS · Kite · NOVARTIS · Fate THERAPEUTICS · artiva

EXPERTISE

50+ Development Programs

Celgene · AMGEN · Bristol-Myers Squibb

PROVEN

5/6 FDA-Approved CAR T Cell Therapies

KYMRIAH® (tisagenlecleucel) Suspension for IV infusion · YESCARTA · TECARTUS · Breyanzi · Abecma



Dr Rebecca McQualter
Chief Operating Officer

AMGEN · NOVARTIS

Dr Eliot BOURK
Chief Business Officer

Kite · Celgene · deallus

Dr Jason LITTEN
Chief Medical Officer

artiva · JUNO THERAPEUTICS



Dr Stephanie ASTROW
VP Translational Sciences

Fate THERAPEUTICS · Kite

Kelly THORNBURG
VP Technical Operations

Kite · XBiotech · AMGEN

CHIMERIC: POSITIONED FOR SUCCESS

2024 Current Progress



MDACC: MD Anderson Cancer Centre/ COH: City of Hope / CWRU: Case Western Reserve University

CHM CDH17
CHM 2101

CHM CDH17 CAR T

PHASE 1/2 CLINICAL TRIAL IN GI CANCERS

OBJECTIVE:
Characterize the safety and tolerability of CDH17 CAR and determine the recommended Phase 2 dose (RP2D) for Phase 2

PRIMARY ENDPOINTS:
- DLT's, Safety Profile
- AE's, CRS, ICANS

SECONDARY ENDPOINTS:
- ORR, DCR, TTR, DOR,
- PFS, OS
- Cellular Kinetics

Colorectal Cancer

NETs

G1, G2, and well-differentiated G3 NETs of the midgut and hindgut with ≤ 55% Ki67 expression

Gastric Cancer

Central laboratory confirmation of CDH17+ tumor expression by IHC (H score ≥ 5) is required.



DOSE ESCALATION

Tumor Specific Dose Confirmation → Tumor Specific Dose Expansion

Upon signal confirmation, dose confirmation and expansion in tumour specific cohorts

All patients must have received at least 1 prior line of systemic anti-cancer treatment in the locally advanced or metastatic setting. Participants must have received or declined FDA-approved and available treatment options

CHM CLTX
CHM 1101

POSITIVE PRELIMINARY PHASE 1A CLINICAL DATA IN RECURRENT/ PROGRESSIVE GLIOBLASTOMA

DISEASE CONTROL RATE

55%

Disease Control Rate (DCR) in heavily pretreated patients

Exceeding historical disease control rates of 20-37%[1]

SURVIVAL

~10 months

Median survival in patients that achieved disease control

14+ months

Survival in two patients that achieved disease control

~7 month survival expectation after first recurrence[2]

SAFETY

Generally, well tolerated

No Dose Limiting Toxicities

No Cytokine Release Syndrome

No Tumour Lysis Syndrome

1. *1. Temozolomide DCR: = 37% Ref: DOI:10.1200/JCO.2009.26.5520 Journal of Clinical Oncology 28, no. 12 (April 20, 2010) 2051-2057; Lomustine DCR: 20% The Lancet Oncology: Volume 20, Issue 1, 1-164, 65*
2. *2. Gallego O. Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 2015 Aug;22(4):e273-81.*

CHM CLTX CAR

ADVANCING DEVELOPMENT TO MULTI-SITE PHASE 1B

CHM CLTX
CHM 1101

OBJECTIVES:
- PFS, OS, ORR
- Safety & Feasibility
- RP2D
- Cellular Kinetics

PATIENT POPULATION:
- Recurrent / progressive glioblastoma

PART A
DOSE CONFIRMATION

440 X 10^6

3-6 PATIENTS

SAFETY & EFFICACY ASSESMENT

PART B
DOSE EXPANSION

440 X 10^6

12-26 PATIENTS

PHASE 2

CHM CORE-NK

CHM CORE-NK DEVELOPMENT PLAN

OPTIMIZING FOR THE FUTURE



1. CHM 0201 Combinations

Exploring novel combinations utilizing NK cells with standard of care therapies

2. CHM 0301 Next Generation Platform

Next generation armored platform development

3. CAR-NK Products

Development of CAR NK products utilizing our CLTX and CDH17 chimeric antigen receptors

CHM CORE-NK

ADVENT-AML PHASE 1B CLINICAL TRIAL

CHM CORE-NK 0201 + AZA + VEN IN FRONT-LINE AML

HIGH UNMET NEED IN AML

Despite treatment advances, outcomes for AML patients not eligible for intensive chemotherapy or allogeneic stem cell transplant are poor

CHM CORE-NK 0201 + AZACITIDINE + VENETOCLAX

A Phase Ib Trial of Azacitidine, Venetoclax and CHM CORE-NK 0201 Allogeneic NK Cells for Acute Myeloid Leukemia
Study Initiation: Q1, 2024
Enrollment: 23 participants

Dose Escalation Eligibility:
Relapse or refractory AML, or MDS/AML with 10% to 19% blasts

Dose Expansion Eligibility:
Newly diagnosed, older/unfit patients with adverse risk AML or MDS/AML

Clinical Trials.gov Identifier: NCT05834244

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center

CHM CORE-NK

CHM CORE-NK 0201 + Vactosertib Re-Opened

FDA APPROVED FIRST EVER TRIAL OF NK CELLS WITH VACTOSERTIB

A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGF-beta Receptor I Inhibitor Vactosertib

Study Initiation: Jan 2023 – paused due to staff issue
Enrollment: 12 Patients
Estimated Completion: reopened April 2024; completion Late 2024

Eligible Patients:
Relapse or refractory solid tumours and hematological malignancies

Clinical Trials.gov Identifier: NCT05400122

CWRU